[ad_1]
The data highlights the powerful anti-tumor activity of multiple tumor models and the potential for combination with other drugs
It is expected to submit an investigational new drug application for MALT1 development drug candidates to the U.S. Food and Drug Administration in the first half of 2022
Schrodinger, Inc. (NASDAQ:Sustainable Development Strategy), its physics-based software platform is changing the way treatment methods and materials are discovered. Today, at the poster meeting of B-cell lymphoma, the new clinic of its Mucosal Associated Lymphoid Tissue Lymphoma Translocation Protein 1 (MALT1) Inhibitor Program was demonstrated The previous data. The 63rd American Society of Hematology (ASH) Annual Meeting and Exposition was held in Atlanta, Georgia. MALT1 is considered as a potential therapeutic target for several non-Hodgkin B-cell lymphomas and chronic lymphocytic leukemia. Schrödinger has identified new MALT1 inhibitors. These inhibitors have shown strong anti-tumor activity in a variety of tumor models, including cell and patient-derived xenograft models, as well as the potential for combination with other drugs, including ibrutinib, etc. Standard care.
“We are pleased that our data strongly emphasizes the therapeutic potential of our MALT1 inhibitors and provides an opportunity to bring potential first-class MALT1 inhibitors to the clinic,” said Dr. Karen Akinsanya, Executive Vice President and Chief Executive Officer. Schrödinger’s biomedical scientist and head of discovery research and development. “We are expected to submit our MALT1 drug candidate IND to the FDA in the first half of 2022.”
The data provided suggests that targeting MALT1 may expand the treatment options for some patients with B-cell lymphoma, such as the activated B-cell (ABC) subtype of diffuse large B-cell lymphoma (DLBCL), and may expand to others B-cell lymphoma Lymphoma, such as mantle cell lymphoma (MCL). In addition, these small molecule MALT1 inhibitors show the potential to be used in combination with Bruton tyrosine kinase (BTK) inhibitors to overcome drug-induced resistance in patients with relapsed/refractory B-cell lymphoma.
Other details about
The full story can be found on Benzinga.com
[ad_2]
Source link
